{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:42:18Z","timestamp":1793400138788,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA166742"],"award-info":[{"award-number":["R01 CA166742"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA097274"],"award-info":[{"award-number":["P50 CA097274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA097274"],"award-info":[{"award-number":["P50 CA097274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA097274"],"award-info":[{"award-number":["P50 CA097274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA195568"],"award-info":[{"award-number":["U01 CA195568"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA097274"],"award-info":[{"award-number":["P50 CA097274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014535","name":"Mayo Clinic Center for Individualized Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014535","id-type":"DOI","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>How to identify follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. Building on a prior study demonstrating the early transformation of FLs with high variant allele frequency (VAF) <jats:italic>BCL2<\/jats:italic> mutations at activation-induced cytidine deaminase (AICDA) sites, we examined 11 AICDA mutational targets, including <jats:italic>BCL2<\/jats:italic>, <jats:italic>BCL6<\/jats:italic>, <jats:italic>PAX5, PIM1<\/jats:italic>, <jats:italic>RHOH<\/jats:italic>, <jats:italic>SOCS<\/jats:italic>, and <jats:italic>MYC<\/jats:italic>, in 199 newly diagnosed grade 1 and 2 FLs. <jats:italic>BCL2<\/jats:italic> mutations with VAF \u226520% occurred in 52% of cases. Among 97 FL patients who did not initially receive rituximab-containing therapy, nonsynonymous <jats:italic>BCL2<\/jats:italic> mutations at VAF \u226520% were associated with increased transformation risk (HR 3.01, 95% CI 1.04\u20138.78, <jats:italic>p<\/jats:italic>\u2009=\u20090.043) and a trend toward shorter event-free survival (EFS, median 20 months with mutations versus 54 months without, <jats:italic>p<\/jats:italic>\u2009=\u20090.052). Other sequenced genes were less frequently mutated and did not increase the prognostic value of the panel. Across the entire population, nonsynonymous <jats:italic>BCL2<\/jats:italic> mutations at VAF \u226520% were associated with decreased EFS (HR 1.55, 95% CI 1.02\u20132.35, <jats:italic>p<\/jats:italic>\u2009=\u20090.043 after correction for FLIPI and treatment) and decreased overall survival after median 14-year follow-up (HR 1.82, 95% CI 1.05\u20133.17, <jats:italic>p<\/jats:italic>\u2009=\u20090.034). Thus, high VAF nonsynonymous <jats:italic>BCL2<\/jats:italic> mutations remain prognostic even in the chemoimmunotherapy era.<\/jats:p>","DOI":"10.1038\/s41408-023-00847-1","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T02:26:43Z","timestamp":1684290403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era"],"prefix":"10.1038","volume":"13","author":[{"given":"Cristina","family":"Correia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4157-3951","authenticated-orcid":false,"given":"Paige E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7904-1651","authenticated-orcid":false,"given":"Anne J.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4712","authenticated-orcid":false,"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.","family":"Eckloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-5472","authenticated-orcid":false,"given":"Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-7145","authenticated-orcid":false,"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"847_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, Lopez-Guillermo A, et al. Follicular lymphoma. Nat Rev Dis Prim. 2019;5:83.","journal-title":"Nat Rev Dis Prim"},{"key":"847_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","volume":"34","author":"JR Cerhan","year":"2020","unstructured":"Cerhan JR. Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am. 2020;34:631\u201346.","journal-title":"Hematol Oncol Clin North Am"},{"key":"847_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/asheducation-2018.1.185","volume":"2018","author":"JP Leonard","year":"2018","unstructured":"Leonard JP, Nastoupil LJ, Flowers CR. Where to start? Upfront therapy for follicular lymphoma in 2018. Hematol Am Soc Hematol Educ Program. 2018;2018:185\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"847_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/hon.2853","volume":"39","author":"B Kahl","year":"2021","unstructured":"Kahl B. High-risk follicular lymphoma: treatment options. Hematol Oncol. 2021;39:94\u201399.","journal-title":"Hematol Oncol"},{"key":"847_CR5","first-page":"97","volume":"36","author":"KE Cahill","year":"2022","unstructured":"Cahill KE, Smith SM. Follicular lymphoma: a focus on current and emerging therapies. Oncology. 2022;36:97\u2013106.","journal-title":"Oncology"},{"key":"847_CR6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"847_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesquieres H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91:1096\u2013101.","journal-title":"Am J Hematol"},{"key":"847_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/hematology.2021000264","volume":"2021","author":"C Casulo","year":"2021","unstructured":"Casulo C. Follicular lymphoma: is there an optimal way to define risk? Hematol Am Soc Hematol Educ Program. 2021;2021:313\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"847_CR9","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.blre.2021.100865","volume":"50","author":"P Mozas","year":"2021","unstructured":"Mozas P, Rivero A, Lopez-Guillermo A. Past, present and future of prognostic scores in follicular lymphoma. Blood Rev. 2021;50:100865.","journal-title":"Blood Rev"},{"key":"847_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.3874430","volume":"228","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto Y, Cossman J, Jaffe E, Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440\u20133.","journal-title":"Science"},{"key":"847_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bjh.17383","volume":"194","author":"E Kumar","year":"2021","unstructured":"Kumar E, Pickard L, Okosun J. Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation. Br J Haematol. 2021;194:810\u201321.","journal-title":"Br J Haematol"},{"key":"847_CR12","doi-asserted-by":"crossref","unstructured":"Gordon MJ, Smith MR, Nastoupil LJ. Follicular lymphoma: the long and winding road leading to your cure? Blood Rev. 2022;57:100992.","DOI":"10.1016\/j.blre.2022.100992"},{"key":"847_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/335440a0","volume":"335","author":"DL Vaux","year":"1988","unstructured":"Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440\u20132.","journal-title":"Nature."},{"key":"847_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.it.2015.07.003","volume":"36","author":"V Chandra","year":"2015","unstructured":"Chandra V, Bortnick A, Murre C. AID targeting: old mysteries and new challenges. Trends Immunol. 2015;36:527\u201335.","journal-title":"Trends Immunol"},{"key":"847_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nri.2016.2","volume":"16","author":"R Casellas","year":"2016","unstructured":"Casellas R, Basu U, Yewdell WT, Chaudhuri J, Robbiani DF, Di Noia JM. Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity. Nat Rev Immunol. 2016;16:164\u201376.","journal-title":"Nat Rev Immunol"},{"key":"847_CR16","first-page":"3894","volume":"63","author":"LA Smit","year":"2003","unstructured":"Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin\u2019s lymphomas of germinal-center phenotype. Cancer Res. 2003;63:3894\u20138.","journal-title":"Cancer Res"},{"key":"847_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/sj.leu.2403323","volume":"18","author":"MS Hardianti","year":"2004","unstructured":"Hardianti MS, Tatsumi E, Syampurnawati M, Furuta K, Saigo K, Nakamachi Y, et al. Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL. Leukemia 2004;18:826\u201331.","journal-title":"Leukemia"},{"key":"847_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05454.x","volume":"129","author":"C Bodor","year":"2005","unstructured":"Bodor C, Bognar A, Reiniger L, Szepesi A, Toth E, Kopper L, et al. Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma. Br J Haematol. 2005;129:373\u20136.","journal-title":"Br J Haematol"},{"key":"847_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.leukres.2007.11.028","volume":"32","author":"AM Halldorsdottir","year":"2008","unstructured":"Halldorsdottir AM, Fruhwirth M, Deutsch A, Aigelsreiter A, Beham-Schmid C, Agnarsson BA, et al. Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma. Leuk Res. 2008;32:1015\u201321.","journal-title":"Leuk Res"},{"key":"847_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.blre.2015.08.002","volume":"30","author":"J Iqbal","year":"2016","unstructured":"Iqbal J, Naushad H, Bi C, Yu J, Bouska A, Rohr J, et al. Genomic signatures in B-cell lymphoma: how can these improve precision in diagnosis and inform prognosis? Blood Rev. 2016;30:73\u201388.","journal-title":"Blood Rev"},{"key":"847_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrc.2017.127","volume":"18","author":"S Huet","year":"2018","unstructured":"Huet S, Sujobert P, Salles G. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat Rev Cancer. 2018;18:224\u201339.","journal-title":"Nat Rev Cancer"},{"key":"847_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"16","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;16:130\u201340.","journal-title":"Cell Rep."},{"key":"847_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46:176\u201381.","journal-title":"Nat Genet"},{"key":"847_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2021.278766","volume":"107","author":"G Cartron","year":"2022","unstructured":"Cartron G, Trotman J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica. 2022;107:7\u201318.","journal-title":"Haematologica."},{"key":"847_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00525-0","volume":"11","author":"K Arushi","year":"2021","unstructured":"Arushi K, Mwangi R, Ansell SM, Habermann TM, Cerhan JR, Strouse C, et al. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer J. 2021;11:133.","journal-title":"Blood Cancer J"},{"key":"847_CR26","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","volume":"5","author":"M Federico","year":"2018","unstructured":"Federico M, Caballero Barrigon MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5:e359\u2013e367.","journal-title":"Lancet Haematol"},{"key":"847_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424\u201335.","journal-title":"Lancet Oncol"},{"key":"847_CR28","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","volume":"32","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32:3096\u2013102.","journal-title":"J Clin Oncol"},{"key":"847_CR29","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","volume":"127","author":"BS Kahl","year":"2016","unstructured":"Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127:2055\u201363.","journal-title":"Blood."},{"key":"847_CR30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med. 1984;311:1471\u20135.","journal-title":"N Engl J Med"},{"key":"847_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/asheducation.V2012.1.433.3798541","volume":"2012","author":"B Kahl","year":"2012","unstructured":"Kahl B. Is there a role for \u201cwatch and wait\u201d in follicular lymphoma in the rituximab era? Hematol Am Soc Hematol Educ Program. 2012;2012:433\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"847_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S1470-2045(14)70066-X","volume":"15","author":"SM Ansell","year":"2014","unstructured":"Ansell SM. Follicular lymphoma: watch and wait is watch and worry. Lancet Oncol. 2014;15:368\u20139.","journal-title":"Lancet Oncol"},{"key":"847_CR33","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/17474086.2020.1818226","volume":"13","author":"E Cencini","year":"2020","unstructured":"Cencini E, Fabbri A, Mecacci B, Bocchia M. How to manage early-stage follicular lymphoma. Expert Rev Hematol. 2020;13:1093\u2013105.","journal-title":"Expert Rev Hematol"},{"key":"847_CR34","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111\u201322.","journal-title":"Lancet Oncol"},{"key":"847_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.16159","volume":"188","author":"S Lockmer","year":"2020","unstructured":"Lockmer S, Ren W, Brodtkorb M, Ostenstad B, Wahlin BE, Pan-Hammarstrom Q, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188:259\u201367.","journal-title":"Br J Haematol"},{"key":"847_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood-2019-130208","volume":"134","author":"V Jurinovic","year":"2019","unstructured":"Jurinovic V, Passerini V, Oestergaard MZ, Knapp A, Mundt K, Araf S, et al. Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Blood. 2019;134:122.","journal-title":"Blood."},{"key":"847_CR37","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139:1684\u201393.","journal-title":"Blood."},{"key":"847_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","volume":"125","author":"C Correia","year":"2015","unstructured":"Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125:658\u201367.","journal-title":"Blood."},{"key":"847_CR39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ajh.24701","volume":"92","author":"S Huet","year":"2017","unstructured":"Huet S, Szafer-Glusman E, Tesson B, Xerri L, Fairbrother WJ, Mukhyala K, et al. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. Am J Hematol. 2017;92:515\u20139.","journal-title":"Am J Hematol"},{"key":"847_CR40","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/ije\/dyx119","volume":"46","author":"JR Cerhan","year":"2017","unstructured":"Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, et al. Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study. Int J Epidemiol. 2017;46:1753\u20131754i.","journal-title":"Int J Epidemiol"},{"key":"847_CR41","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754\u201360.","journal-title":"Bioinformatics."},{"key":"847_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygeno.2011.05.009","volume":"98","author":"Y Kong","year":"2011","unstructured":"Kong Y. Btrim: a fast, lightweight adapter and quality trimming program for next-generation sequencing technologies. Genomics. 2011;98:152\u20133.","journal-title":"Genomics."},{"key":"847_CR43","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297\u2013303.","journal-title":"Genome Res"},{"key":"847_CR44","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841\u20132.","journal-title":"Bioinformatics."},{"key":"847_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/0471250953.bi1112s47","volume":"47","author":"AR Quinlan","year":"2014","unstructured":"Quinlan AR. BEDTools: the Swiss-Army Tool for genome feature analysis. Curr Protoc Bioinforma. 2014;47:11\u201334.","journal-title":"Curr Protoc Bioinforma"},{"key":"847_CR46","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/ng.680","volume":"42","author":"Y Li","year":"2010","unstructured":"Li Y, Vinckenbosch N, Tian G, Huerta-Sanchez E, Jiang T, Jiang H, et al. Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet. 2010;42:969\u201372.","journal-title":"Nat Genet"},{"key":"847_CR47","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature09534","volume":"467","author":"C Genomes Project","year":"2010","unstructured":"Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061\u201373.","journal-title":"Nature."},{"key":"847_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"C Genomes Project","year":"2012","unstructured":"Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56\u201365.","journal-title":"Nature."},{"key":"847_CR49","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/bioinformatics\/btu137","volume":"30","author":"JP Kocher","year":"2014","unstructured":"Kocher JP, Quest DJ, Duffy P, Meiners MA, Moore RM, Rider D, et al. The biological reference repository (BioR): a rapid and flexible system for genomics annotation. Bioinformatics. 2014;30:1920\u20132.","journal-title":"Bioinformatics."},{"key":"847_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u2013448.","journal-title":"J Am Stat Assoc"},{"key":"847_CR51","doi-asserted-by":"publisher","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","volume":"13","author":"R Kridel","year":"2016","unstructured":"Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, et al. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med. 2016;13:e1002197.","journal-title":"PLoS Med"},{"key":"847_CR52","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2009.23.4245","volume":"28","author":"GS Nowakowski","year":"2010","unstructured":"Nowakowski GS, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol. 2010;28:412\u20137.","journal-title":"J Clin Oncol"},{"key":"847_CR53","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272\u20138.","journal-title":"J Clin Oncol"},{"key":"847_CR54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10495-009-0337-7","volume":"14","author":"J Eeva","year":"2009","unstructured":"Eeva J, Nuutinen U, Ropponen A, Matto M, Eray M, Pellinen R, et al. The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells. Apoptosis 2009;14:687\u201398.","journal-title":"Apoptosis"},{"key":"847_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","volume":"8","author":"TM Pierpont","year":"2018","unstructured":"Pierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab-The World\u2019s First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018;8:163.","journal-title":"Front Oncol"},{"key":"847_CR56","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","volume":"4","author":"CM Patterson","year":"2021","unstructured":"Patterson CM, Balachander SB, Grant I, Pop-Damkov P, Kelly B, McCoull W, et al. Design and optimisation of dendrimer-conjugated Bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021;4:112.","journal-title":"Commun Biol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00847-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00847-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00847-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T02:27:03Z","timestamp":1684290423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00847-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["847"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00847-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L.F. has received research funding from Seattle Genetics, is an inventor of technology for which Mayo Clinic holds unlicensed patents, and is an inventor of intellectual property licensed to Zeno Pharmaceuticals. J.R.C. has received research funding from Genentech. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}